Article content
New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.
I’m sitting on the ground with seven others, huddled around a mass of lumpy, grey matter that quickly turns to powder under the pounding of hammers. Beside us are a small dipping pool, some mulberry trees and a whitewashed house crawling with purple bougainvillaea, from which two dogs drift in and out to inspect our work.
“This is pretty therapeutic, isn’t it?” someone says above the clattering of tools, as flower-dappled light dances on a canopy that’s shielding us from the hot Andalucían sun.
We’re on a four-day wild clay ceramics retreat at Las Mecias, a regenerative farm in Spain’s Alpujarras, an idyllic valley just over an hour and a half south-east of Granada in the Sierra Nevada mountains. The course is a collaboration between Las Mecias’s Dutch owners, Laura and Nina, and Spaniards Milena and Julia from Tierra de Arcillas, a local ceramics studio. They connected through Instagram and things evolved from there.
The aim is to teach guests how to find, forage, process and fire ceramics from locally sourced wild clay in a more sustainable approach to pottery. They run a handful of workshops in spring and autumn when temperatures are more bearable.
I found Las Mecias while looking for pottery retreats in Spain, already hooked after one wheel-throwing workshop months earlier. That class came towards the end of a debilitating bout of depression and anxiety that had left me unable to work or function properly for months. At the wheel, I felt the dark cloud lift temporarily and anxious ruminations evaporated like water on a hot stove.
This time I’d be hand-building pottery for the first time. Las Mecias is located in exactly the kind of place those tired of the city long to escape to. Set off a dusty track, a few minutes from the picturesque mountainside pueblo (village) of Cástaras, the 2-hectare (5-acre) off-grid organic farm and retreat space is a natural haven dotted with olive and fruit trees, wildflowers and vegetable gardens.
The accommodation comprises a tiny home (a dinky caravan with a sundeck), a good-sized Mongolian-style yurt, and a minimalist Mediterranean two-bedroom casita (small house) with a kitchen, living room and terrace. All have spellbinding views over the low Sierra de la Contraviesa, which is speckled with vines and cortijos (farmhouses).
Our group includes a model from Taiwan, a Spanish project manager, a French yoga teacher, a Polish AI expert and a clarinettist from High Wycombe. My girlfriend and I are staying off-site at El Huerto de Lobras – a collection of bucolic apartments run by an endearing abuela (grandmother) named Ana.
The first day begins with introductions followed by a lesson on clay theory and a foraging mission led by Milena and Julia. The warm, spirited couple, who met in Barcelona and now live together in Almería, run Tierras de Arcillas in the foothills of the Alpujarras Almeriense.
Sick of being stuck behind a screen, Julia, a graphic designer, took a ceramics course in Barcelona where she became fascinated with the origins of clay. Lighting designer Milena was converted later when trawling the hills of Almería, charmed by the earth’s colours and textures.
Armed with pick-spades, we all set off to roam the marbled hills, searching for good clay. “See those cracks? That’s a good sign,” Julia says, leading us to a jagged, light-grey shard of mountain. We test the quality by removing stones, adding a drop of water, making a ball, then a tiny sausage, then a ring. The ring is the goal as it means the clay is 70% pure. After a positive test, we hack away frantically in clouds of dust, filling buckets like middle-class miners.
Back at the farm, Laura and Nina prepare dinner. Between them, the couple have worked in kitchens across the UK, Australia, Denmark and the Netherlands, so meals at Las Mecias are exceptional. For breakfast, there’s freshly made sourdough loaves, homemade quince, strawberry and plum jams and plates of watermelon, mango and loquat. Lunches feature Ottolenghi-worthy salads, while dinners span Indonesian, Mediterranean and Middle-Eastern cuisine – served with their own olive oil and natural wine.
Between meals, we wander the grounds, flop in deck chairs and hammocks staring out to snow-capped peaks, and work on our pieces. One of the group – me – makes an ugly olive dish, which looks like a flower that’s been stamped on. Others craft impressive vases, plates, cups, trays and bird feeders.
The workshop is well structured and flows naturally. Each part feels like a therapeutic technique. Foraging becomes my grounding ritual. Processing clay by removing impurities echoes filtering out negative beliefs. Deep discussions replace the rawness of therapy. And nutritious meals, quality sleep and abundant nature restore the soul.
Over the days, my mind quietens. It’s not a resounding silence. I’m not cured from the mental health issues that have plagued me for two decades, but I feel calmer. I’m attuned to the hum of bees and the crunch of stones underfoot. Inconveniences morph into joyful moments: getting stuck behind a farmer herding goats on a winding mountain road, having no phone signal anywhere, and being woken by the local church choir.
The four-day workshop culminates in a final ritual, where we fire up the handbuilt kiln and load it with our pieces. Between shifts gathering sticks and stoking the fire, we take turns dipping in the pool.
After sunset, Laura makes a pizza while Nina glides around with homemade wine and jugs of shrub – a refreshing drink made from fruit and vinegar.
Perching on hay bales, swigging wine and sharing stories, we cheer as the kiln’s temperature hits its century milestones, before reaching a high of 917F (492C). Sealing the oven, Milena and Julia chant a symbolic blessing, “protectora, ponle lo que falta y quitale lo que le sobra”, roughly translated to, “protector, provide us with what we lack and remove what isn’t needed”, before we retire to bed.
The next morning, we gather around the kiln and remove bricks, one by one. There’s no telling what’s survived: the fire decides. Perhaps a final reminder that acceptance and letting go is part of the process. Cheers erupt and compliments are exchanged as the first pieces emerge intact.
As we say our goodbyes, one member of the group leaves us with a final moment of reflection. “Honestly, I didn’t really care what mine turned out like. It didn’t matter if it cracked or exploded. I just enjoyed the process and would’ve accepted whatever happened.”
The retreat was provided by Las Mecias and Tierra de Arcillas, which offer three-night, four-day introduction to wild clay workshops, including accommodation, three dinners, three breakfasts and two lunches, and over 15 hours of theory and practical instruction. Prices from €580, based on a shared stay in a yurt with an outside bathroom. The next workshop is 16-19 October; 2026 dates to be announced late in October
Article content
New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
or
Article content
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA’s patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training.
Article content
Article content
Article content
“It’s generally assumed that AI can only make accurate predictions if it has seen similar data before,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “But this benchmark proves otherwise: LENSai accurately mapped antibody binding sites on entirely new antibody – protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn’t always need massive data to be powerful and accurate – it just needs the right kind.”
Article content
Top Stories
Get the latest headlines, breaking news and columns.
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Thanks for signing up!
A welcome email is on its way. If you don’t see it, please check your junk folder.
The next issue of Top Stories will soon be in your inbox.
We encountered an issue signing you up. Please try again
Article content
LENSai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins – helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENSai delivers results in hours – using just the digital sequences – cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments.
Article content
In a new benchmark study, LENSai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENSai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology.
Article content
The consistent performance on entirely new, unseen complexes confirms that LENSai’s artificial intelligence can reliably analyze and predict antibody binding – even for molecules outside its training set. This breakthrough demonstrates LENSai’s power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery.
Article content
Why This Benchmark Matters
Article content
In the new study, LENSai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples – proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays.
Article content
Article content
What It Means for Partners and Investors
Article content
With LENSai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets – positioning the company and its investors at the forefront of AI-driven antibody therapeutics.
Article content
For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENSai Epitope Mapping.
Article content
The first highlights performance on a
Article content
“seen” target
Article content
, where the system was trained on related data. The second – featured in this press release – demonstrates LENS
Article content
ai
Article content
’s breakthrough ability to accurately map binding sites on a completely
Article content
“unseen” target
Article content
, with no prior exposure to the antibody, the antigen, or their structure.
Article content
Article content
These examples underscore how LENSai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness.
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or by statements that certain actions, events, or results “may,” “will,” “could,” or “might” occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company’s AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company’s future scientific, commercial, and strategic developments.